CD30 expression in high-risk acute myeloid Leukemia and myelodysplastic syndromes

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 3, 2013, Pages 307-314

  Zheng, Wenli ^a   Medeiros, L Jeffrey ^a   Hu, Ying ^a   Powers, Linda ^a   Cortes, Jorge E ^a   Ravandi Kashani, Farhad ^a   Kantarjian, Hagop H ^a   Wang, Sa A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute myeloid leukemia; CD30; Flow cytometry; Immunohistochemistry; Myelodysplastic syndromes

Indexed keywords

CD135 ANTIGEN; CD30 ANTIGEN; CD34 ANTIGEN; NUCLEOPHOSMIN; RAS PROTEIN; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; BLAST CELL CRISIS; BONE MARROW; BONE MARROW BIOPSY; CANCER STAGING; CELL DIFFERENTIATION; CHROMOSOME 3Q; CHROMOSOME 5; CYTOGENETICS; DRUG TARGETING; FEMALE; FLOW CYTOMETRY; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MYELOBLAST; MYELODYSPLASTIC SYNDROME; RECURRENT DISEASE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD30; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; YOUNG ADULT;

EID: 84877760313     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2012.12.006     Document Type: Article

References (33)

1. B. Oran, D.G. Weisdorf Survival for older patients with AML: a population based study Haematologica 97 2012 1916 1924
2. S. Kayser, K. Döhner, J. Krauter The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML Blood 117 2011 2137 2145
3. M.L. Smith, R.K. Hills, D. Grimwade Independent prognostic variables in acute myeloid leukaemia Blood Rev 25 2011 39 51
4. X. Zhu, Y. Ma, D. Liu Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights J Hematol Oncol 3 2010 17
5. D. Hoelzer Novel antibody-based therapies for acute lymphoblastic leukemia Hematology Am Soc Hematol Educ Program 2011 2011 243 249
6. D.A. Thomas, S. O'Brien, S. Faderl Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia J Clin Oncol 28 2010 3880 3889
7. H. Kantarjian, D. Thomas, J. Jorgensen Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study Lancet Oncol 13 2012 403 411
8. A.D. Ricart Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin Clin Cancer Res 17 2011 6417 6427
9. J. Katz, J.E. Janik, A. Younes Brentuximab vedotin (SGN-35) Clin Cancer Res 17 2011 6428 6436
10. A. Younes, N.L. Bartlett, J.P. Leonard Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas N Engl J Med 363 2010 1812 1821
11. A. Rothe, S. Sasse, H. Goergen Brentuximab vedotin for relapsed or refractory CD30-positive hematologic malignancies: the German Hodgkin Study Group experience Blood 120 2012 1470 1472
12. M. Masuya, K. Kita, N. Shimizu Biologic characteristics of acute leukemia after myelodysplastic syndrome Blood 81 1993 3388 3394 (Pubitemid 23172925)
13. M.W. Bekkenk, P.M. Jansen, C.J. Meijer CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature Ann Oncol 15 2004 1097 1108 (Pubitemid 39089788)
14. A. Lemes, S. De La Iglesia, C. Santana t(2; 5) associated with a histiocytic-monocytic neoplasm Leuk Lymphoma 41 2001 429 433
15. S.A. Pileri, S. Ascani, M.C. Cox Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients Leukemia 21 2007 340 350 (Pubitemid 46158129)
16. A.T. Fathi, F.I. Preffer, H. Sadrzadeh CD30 expression in acute myeloid leukemia is associated with FLT3-internal tandem duplication mutation and leukocytosis Leuk Lymphoma September 28, 2012 [E-pub ahead of print]
17. D.A. Arber, R.D. Brunning, A. Orazi Acute myeloid leukemia, not otherwise specified S.H. Swerdlow, E. Campo, N.L. Harris, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 4th ed. 2008 IARC Lyon, France 134 136
18. D. Grimwade, R.K. Hills, A.V. Moorman Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials Blood 116 2010 354 365
19. P. Greenberg, C. Cox, M.M. LeBeau International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 1997 2079 2088 (Pubitemid 27132124)
20. K. Hussein, A.D. Pardanani, D.L. Van Dyke International prognostic scoring system-independent cytogenetic risk categorization in primary myelofibrosis Blood 115 2010 496 499
21. A. Bains, R. Luthra, L.J. Medeiros FLT3 and NPM1 mutations in myelodysplastic syndromes: frequency and potential value for predicting progression to acute myeloid leukemia Am J Clin Pathol 135 2011 62 69
22. P. Lin, D. Jones, L.J. Medeiros Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia Am J Clin Pathol 126 2006 530 533 (Pubitemid 44498502)
23. Z. Zuo, S.S. Chen, P.K. Chandra Application of COLD-PCR for improved detection of KRAS mutations in clinical samples Mod Pathol 22 2009 1023 1031
24. R. Horie, T. Watanabe CD30: expression and function in health and disease Semin Immunol 10 1998 457 470 (Pubitemid 28564375)
25. E. Oflazoglu, I.S. Grewal, H. Gerber Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases Adv Exp Med Biol 647 2009 174 185
26. R. Chiarle, A. Podda, G. Prolla CD30 in normal and neoplastic cells Clin Immunol 90 1999 157 164 (Pubitemid 29162160)
27. P. Valent, K. Sotlar, H.P. Horny Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms Leuk Lymphoma 52 2011 740 744
28. K. Sotlar, S. Cerny-Reiterer, K. Petat-Dutter Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis Mod Pathol 24 2011 585 595
29. V. Gattei, M. Degan, F.M. Rossi CD30 ligand (CD30L)-expressing acute myeloid leukemias: a new model of paracrine interactions for the regulation of blast cells proliferation Leuk Lymphoma 35 1999 21 35 (Pubitemid 29454400)
30. V. Gattei, M. Degan, A. Gloghini CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin Blood 89 1997 2048 2059 (Pubitemid 27132121)
31. M. Watanabe, K. Itoh, T. Togano Ets-1 activates overexpression of JunB and CD30 in Hodgkin's lymphoma and anaplastic large-cell lymphoma Am J Pathol 180 2012 831 838
32. G.Z. Rassidakis, A. Thomaides, C. Atwell JunB expression is a common feature of CD30+ lymphomas and lymphomatoid papulosis Mod Pathol 18 2005 1365 1370 (Pubitemid 41348656)
33. A. Rezaei, M. Adib, F. Mokarian Leukemia markers expression of peripheral blood vs bone marrow blasts using flow cytometry Med Sci Monit 9 2003 CR359 CR362